Background/Aim: The relationship between the hypothalamic-pituitary-thyroid (HPT) axis and the serotonergic (5-hydroxytryptamine, 5-HT) system is not clear. The aim of the study was to determine platelet biochemical markers (5-HT concentration and monoamine oxidase B, MAO-B, activity) in hypothyroid patients. Methods: The study included 25 medication-free female hypothyroid patients in postoperative follow-up after total thyroidectomy due to papillary thyroid carcinoma, who had not been treated with synthetic thyroxine (T4) for 4 weeks, and 44 age-matched euthyroid healthy women. The platelet 5-HT concentration, platelet MAO-B activity, total T4 and thyroid-stimulating hormone (TSH) levels were determined using spectrofluorimetric methods, radioimmunoassay and fluoroimmunoassay, respectively. Results: Hypothyroid patients had significantly higher TSH, significantly lower T4 levels and platelet 5-HT concentrations, and unchanged platelet MAO-B activity than healthy subjects. A positive correlation was found between the 5-HT concentration and platelet MAO-B activity, and between the platelet MAO-B activity and T4 in control subjects. Conclusions: Reduced platelet 5-HT concentrations in hypothyroid patients suggests a complex interaction between the 5-HT system and HPT axis activity, which could be related to the frequent occurrence of depressive symptoms in hypothyroid patients. The determination of platelet 5-HT concentrations should be considered a diagnostic tool for the evaluation of depressive symptoms in hypothyroid patients during the hormone withdrawal procedure.

Keywords:
5-Hydroxytryptamine, platelet, Monoamine oxidase B, platelet, Hypothyroidism, Thyroxine, Thyroid-stimulating hormone
1.
Ahmed OM, El-Gareib AW, El-bakry AM, El-Tawab SMA, Ahmed RG: Thyroid hormones states and brain development interactions. Int J Dev Neurosci 2008;26:147–209.
2.
Bauer M, Heinz A, Whybrow PC: Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatr 2002;7:140–156.
3.
Sandrini M, Vitale G, Vergoni AV, Ottani A, Bertolini A: Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain. Life Sci 1996;58:1551–1559.
4.
Strawn JR, Ekhator NN, D’Souza BB, Geraciotti TD, Geraciotti JR: Pituitary-thyroid state correlates with central dopaminergic and serotonergic activity in healthy humans. Neuropsychobiology 2004;49:84–87.
5.
Newman M, Agid O, Gur E, Lerer B: Pharmacological mechanisms of T3 augmentation of antidepressant action. International J Neuropsychopharmacol 2003;3:187–191.
6.
Viquerie N, Langin D: Effects of thyroid hormone and gene expression. Curr Opin Clin Nutr Metab Care 2003;6:377–381.
7.
Singhal RL, Rastogi RB, Hrdina PD: Brain biogenic amines and altered thyroid function. Life Sci 1975;17:1617–1626.
8.
Ito JM, Valcana T, Timiras PS: Effect of hypo- and hyperthyroidism on regional monamine metabolism in the adult rat brain. Neuroendocrinology 1977;24:55–64.
9.
Savard P, Merand Y, DiPaolo T, Dupont A: Effect of neonatal hypothyroidism on the serotonin system of the rat brain. Brain Res 1984;292:99–108.
10.
Henley WN, Chen X, Klettner C, Bellush LL, Notestine MA: Hypothyroidism increases serotonin turnover and sympathetic activity in the adult rat. Can J Physiol Pharmacol 1991;69:205–210.
11.
Vanderpump MP, Tunbridge WM: Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 2002;12:839–847.
12.
Forman-Hoffman V, Philibert RA: Lower TSH and higher T4 levels are associated with current depressive syndrome in young adults. Acta Psychiatr Scand 2006;114:132–139.
13.
Łojko D, Rybakowski JK: L-Thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 2007;103:253–256.
14.
Sjöberg S, Eriksson M, Nordin C: L-Thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Eur J Endocrinol 1998;139:493–497.
15.
Cleare AJ, McGregor A, Keane VO: Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol 1995;43:713–719.
16.
Kulikov A, Moreau X, Jeanningros R: Effects of experimental hypothyroidism on 5-HT1A, 5-HT2A receptors, 5-HT uptake sites and tryptophan hydroxylase activity in mature rat brain. Neuroendocrinology 1999;69:453–459.
17.
Nemeroff CB: Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002;36:6–23.
18.
Moorley JE: Neuroendocrine control of thyrotropin secretion. Endocr Rev 1981;2:396–436.
19.
Howland RH: Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry 1993;54:47–54.
20.
Nemeroff CB: Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. J Clin Psychiatry 1989;50:13–20.
21.
Prange AJ, Wilson IC, Lara PP, Alltop LB, Breese GR: Effects of thyrotropin-releasing hormone in depression. Lancet 1972;ii:999–1002.
22.
Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F: Forced swimming test and fluxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res 2002;143:191–197.
23.
Muck-Šeler D, Jakovljević M, Pivac N: Platelet 5-HT concentrations and suicidal behaviour in recurrent major depression. J Affect Disord 1996;39:73–80.
24.
Muck-Seler D, Pivac N, Sagud M, Mustapic M, Jakovljevic M: The effects of serotonin uptake inhibitors on platelet serotonin: from basic to clinical research; in Shirley AC (ed): Trends in Serotonin Uptake Inhibitors Research. New York, Nova Science, 2005, pp 29–53.
25.
Muck-Seler D, Pivac N, Jakovljević M: Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. J Neural Transm 1999;106:337–347.
26.
Pivac N, Muck-Seler D, Mustapic M, Sagud M, Darko Marcinko D, Deželjin M, Jakovljevic M: Peripheral biological markers and treatment response in schizophrenia; in French DP (ed): Schizophrenic Psychology: New Research. New York, Nova Science, 2006, pp. 319–370.
27.
Blardi P, Palazzuoli A, de Lalla A, Auteri A: Variations of peripheral markers of serotoninergic system in selected vascular patients. Nutr Metab Cardiovasc Dis 2006;16:210–214.
28.
Fogel WA, Lewinski A, Jochem J: Histamine in food: is there anything to worry about ? Biochem Soc Trans 2007;35:349–352.
29.
Fetkovska N: Platelet activation by low-density lipoprotein and serotonin: the effects of calcium antagonists. J Cardiovasc Pharmacol 1992;19:S25–S28.
30.
Oreland L, Hallman J, Damberg M: Platelet MAO and personality-function and dysfunction. Curr Med Chem 2004;11:2007–2016.
31.
Fagervall I, Ross SB: A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. J Neurochem 1986;47:569–576.
32.
Licata G, Davi G, Scaglione R, Dichiara MA, Catalano I, Strano A: Platelet function in hypo- and hyperthyroidism. Boll Soc Ital Biol Sper 1989;65:847–852.
33.
Ford HC, Carter JM: Moderate, chronic hypothyroidism does not lead to more small-sized platelets in the circulation. Thromb Haemost 1988;60:524.
34.
Coban E, Yazicioglu G, Ozdogan M: Platelet activation in subjects with subclinical hypothyroidism. Med Sci Monit 2007;13:211–214.
35.
Guimaraes V, DeGroot LJ: Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996;6:69–73.
36.
Mück-Šeler D, Pivac N, Sagud M, Jakovljević M, Mihaljevic-Peleš A: The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1235–1243.
37.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
38.
Mueller-Oerlinghausen B, Roggenbach J, Franke L: Serotonergic platelet markers of suicidal behaviour – do they really exist? J Affect Disord 2004;79:13–24.
39.
Pivac N, Kozarić-Kovačić D, Mustapić M, Deželjin M, Nenadić-Šviglin K, Muck-Šeler D: New research on alcohol abuse and alcoholism: peripheral biological markers in alcoholism; in Walcott TA (ed): Drug and Alcohol Abuse Research Focus. New York, Nova Science, 2007, pp 1–62.
40.
Ljubicic D, Stipcevic T, Pivac N, Jakovljevic M, Muck-Seler D: The influence of daylight exposure on platelet 5-HT levels in patients with major depression and schizophrenia. J Photochem Photobiol B 2007;89:63–69.
41.
Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A: Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 2000;73:144–149.
42.
Leibenluft E, Fiero PL, Rubinow DR: Effects of menstrual cycle on dependent variables in mood disorder research. Arch Gen Psychiatry 1994;51:761–781.
43.
Guicheney P, Leger D, Barrat J, Trevoux R, De Lignieres B, Roques P, Garnier JP, Boyers, P, Grenier J, Dreux C, Meyer P: Platelet serotonin content and plasma tryptophan in peri- and post-menopausal women: variations with plasma estrogen levels and depressive symptoms. Eur J Clin Invest 1988;18:297–304.
44.
Muck-Seler D, Pivac N, Mustapic M, CrnceZ, Jakovljevic M, Sagud M: Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004;127:217–226.
45.
Vaccari A, Biassoni R, Timiras P: Selective effects of neonatal hypothyroidism on monoamine oxidase activities in the rat brain. J Neurochem 1983;40:1019–1025.
46.
Oreland L: Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology 2004;25:79–89.
47.
Nishi K, Mück-Šeler D, Hasegawa S, Watanabe A, Diksic M: Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: an autoradiographic study. Brain Res Bull 2006;70:368–377.
48.
Denicoff KD, Joffe RT, Lakshmanan MC, Robbins J, Rubinow DR: Neuropsychiatric manifestations of altered thyroid state. Am J Psychiatry 1990;147:94–99.
49.
Berrios GE, Leysen A, Samuel C, Dowson J: Psychiatric morbidity following total and partial thyroidectomy. Acta Psychiatr Scand 1985;72:369–373.
50.
Montero-Pedrazuela A, Venero C, Lavado-Autric R, Fernandez-Lamo I, Garcia-Verdugo JM, Bernal J: Modulation of adult hippocampal neurogenesis by thyroid hormones: implications in depressive-like behavior. Mol Psychiatr 2006;11:361–371.
51.
Tejani-Butt SM, Yang J, Kaviani A: Time course of altered thyroid states on 5-HT1A receptors and 5-HT uptake sites in rat brain: an autoradiographic analysis. Neuroendocrinology 1993;57:1011–1018.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.